Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

被引:65
|
作者
Bahit, M. Cecilia [1 ]
Lopes, Renato D. [2 ]
Wojdyla, Daniel M. [2 ]
Held, Claes [3 ]
Hanna, Michael [4 ]
Vinereanu, Dragos [5 ]
Hylek, Elaine M. [6 ]
Verheugt, Freek [7 ]
Goto, Shinya [8 ]
Alexander, John H. [2 ]
Wallentin, Lars [3 ]
Granger, Christopher B. [2 ]
机构
[1] INECO, Neurociencias Orono Rosario, Santa Fe, NM, Argentina
[2] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[3] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Univ Med & Pharm Carol Davila, Bucharest, Romania
[6] Boston Univ, Med Ctr, Boston, MA USA
[7] Onze Lieve Vrouwe Gasthuis OLVG, Heartctr, Amsterdam, Netherlands
[8] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
关键词
HEMORRHAGE; DABIGATRAN; THERAPY; STROKE; RISK;
D O I
10.1136/heartjnl-2016-309901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). Methods We included patients who received >= 1 dose of study drug (n= 18 140). Non-major bleeding was defined as the first bleeding event considered to be clinically relevant non-major (CRNM) or minor bleeding, and not preceded by a major bleeding event. Results Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Like major bleeding, non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI 0.63 to 0.75). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%). Medical or surgical intervention was similar among patients with non-major bleeding on warfarin versus apixaban (24.7% vs 24.5%). A change in antithrombotic therapy (58.6% vs 50.0%) and permanent study drug discontinuation (5.1% (61) vs 3.6% (30), p=0.10) was numerically higher with warfarin than apixaban. CRNM bleeding was independently associated with an increased risk of overall death (adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04). Conclusions In ARISTOTLE, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. CRNM bleeding was independently associated with a higher risk of death and subsequent major bleeding. Our results highlight the importance of any severity of bleeding in patients with AF treated with anticoagulation therapy and suggest that non-major bleeding, including minor bleeding, might not be minor.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [1] Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial
    Bahit, M. C.
    Lopes, R. D.
    Wojdyla, D. M.
    Held, C.
    Hanna, M.
    Vinereanu, D.
    Goto, S.
    Alexander, J. H.
    Wallentin, L.
    Granger, C. B.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 338 - 339
  • [2] Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
    Hylek, Elaine M.
    Held, Claes
    Alexander, John H.
    Lopes, Renato D.
    De Caterina, Raffaele
    Wojdyla, Daniel M.
    Huber, Kurt
    Jansky, Petr
    Steg, Philippe Gabriel
    Hanna, Michael
    Thomas, Laine
    Wallentin, Lars
    Granger, Christopher B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (20) : 2141 - 2147
  • [3] Apixaban versus Warfarin in Patients with Atrial Fibrillation
    Granger, Christopher B.
    Alexander, John H.
    McMurray, John J. V.
    Lopes, Renato D.
    Hylek, Elaine M.
    Hanna, Michael
    Al-Khalidi, Hussein R.
    Ansell, Jack
    Atar, Dan
    Avezum, Alvaro
    Cecilia Bahit, M.
    Diaz, Rafael
    Easton, J. Donald
    Ezekowitz, Justin A.
    Flaker, Greg
    Garcia, David
    Geraldes, Margarida
    Gersh, Bernard J.
    Golitsyn, Sergey
    Goto, Shinya
    Hermosillo, Antonio G.
    Hohnloser, Stefan H.
    Horowitz, John
    Mohan, Puneet
    Jansky, Petr
    Lewis, Basil S.
    Luis Lopez-Sendon, Jose
    Pais, Prem
    Parkhomenko, Alexander
    Verheugt, Freek W. A.
    Zhu, Jun
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11): : 981 - 992
  • [4] Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone: nationwide cohort study
    Hansson, Astrid Fritz
    Modica, Angelo
    Renlund, Henrik
    Christersson, Christina
    Held, Claes
    Batra, Gorav
    [J]. OPEN HEART, 2024, 11 (01):
  • [5] History of Bleeding and Outcomes with Apixaban versus Warfarin in Patients with Atrial Fibrillation in the ARISTOTLE Trial
    De Caterina, Raffaele
    Andersson, Ulrika
    Alexander, John H.
    Bahit, M. Cecilia
    Commerford, Patrick J.
    Goto, Shinya
    Granger, Christopher B.
    Hanna, Michael
    Held, Claes
    Hohnloser, Stefan H.
    Hylek, Elaine M.
    Lanas, Fernando
    Lopes, Renato D.
    Lopez-Sendon, Jose L.
    Wallentin, Lars
    [J]. CIRCULATION, 2014, 130
  • [6] Critique of Apixaban Versus Warfarin in Patients With Atrial Fibrillation
    Nedeltchev, Krassen
    [J]. STROKE, 2012, 43 (03) : 922 - 923
  • [7] Apixaban versus Warfarin in Atrial Fibrillation
    Vassiliou, Vassilios S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (01): : 88 - 88
  • [8] History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
    De Caterina, Raffaele
    Andersson, Ulrika
    Alexander, John H.
    Al-Khatib, Sana M.
    Bahit, M. Cecilia
    Goto, Shinya
    Hanna, Michael
    Held, Claes
    Hohnloser, Stefan
    Hylek, Elaine M.
    Lanas, Fernando
    Lopes, Renato D.
    Lopez-Sendon, Jose
    Renda, Giulia
    Horowitz, John
    Granger, Christopher B.
    Wallentin, Lars
    [J]. AMERICAN HEART JOURNAL, 2016, 175 : 175 - 183
  • [9] Apixaban versus warfarin in patients with atrial fibrillation: examination of ARISTOTLE
    Szczerba, Ewa
    [J]. KARDIOLOGIA POLSKA, 2012, 70 (02) : 196 - 200
  • [10] Apixaban versus Warfarin in Atrial Fibrillation REPLY
    Mega, Jessica L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (01): : 89 - 90